Publication:
SEOM clinical guidelines for the treatment of head and neck cancer (2020).

dc.contributor.authorMesia, R
dc.contributor.authorIglesias, L
dc.contributor.authorLambea, J
dc.contributor.authorMartínez-Trufero, J
dc.contributor.authorSoria, A
dc.contributor.authorTaberna, M
dc.contributor.authorTrigo, J
dc.contributor.authorChaves, M
dc.contributor.authorGarcía-Castaño, A
dc.contributor.authorCruz, J
dc.date.accessioned2023-02-09T10:43:32Z
dc.date.available2023-02-09T10:43:32Z
dc.date.issued2021-02-26
dc.description.abstractHead and neck cancers (HNC) are defined as malignant tumours located in the upper aerodigestive tract and represents 5% of oncologic cases in adults in Spain. More than 90% of these tumours have squamous histology. In an effort to incorporate evidence obtained since 2017 publication, the Spanish Society of Medical Oncology (SEOM) presents an update of the squamous cell HNC diagnosis and treatment guideline. Most relevant diagnostic and therapeutic changes from the last guideline have been updated: introduction of sentinel node biopsy in early oral/oropharyngeal cancer treated with surgery, concomitant radiotherapy with weekly cisplatin 40 mg/m2 in the adjuvant setting, new approaches for HPV-related oropharyngeal cancer and new treatments with immune-checkpoint inhibitors in recurrent/metastatic disease.
dc.identifier.doi10.1007/s12094-020-02533-1
dc.identifier.essn1699-3055
dc.identifier.pmcPMC8057973
dc.identifier.pmid33635468
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8057973/pdf
dc.identifier.unpaywallURLhttps://link.springer.com/content/pdf/10.1007/s12094-020-02533-1.pdf
dc.identifier.urihttp://hdl.handle.net/10668/17244
dc.issue.number5
dc.journal.titleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
dc.journal.titleabbreviationClin Transl Oncol
dc.language.isoen
dc.organizationHospital Universitario Virgen de la Victoria
dc.organizationÁrea de Gestión Sanitaria Sur de Sevilla
dc.organizationAGS - Sur de Sevilla
dc.page.number913-921
dc.pubmedtypeJournal Article
dc.pubmedtypePractice Guideline
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectChemoradiotherapy
dc.subjectHead and neck cancer
dc.subjectHuman papillomavirus
dc.subjectImmunotherapy
dc.subject.meshAlphapapillomavirus
dc.subject.meshChemoradiotherapy, Adjuvant
dc.subject.meshCisplatin
dc.subject.meshHead and Neck Neoplasms
dc.subject.meshHumans
dc.subject.meshImmune Checkpoint Inhibitors
dc.subject.meshMedical Oncology
dc.subject.meshMouth Neoplasms
dc.subject.meshNeoplasm Staging
dc.subject.meshOrgan Sparing Treatments
dc.subject.meshOropharyngeal Neoplasms
dc.subject.meshRadiation-Sensitizing Agents
dc.subject.meshRadiotherapy, Adjuvant
dc.subject.meshSentinel Lymph Node Biopsy
dc.subject.meshSocieties, Medical
dc.subject.meshSpain
dc.subject.meshSquamous Cell Carcinoma of Head and Neck
dc.titleSEOM clinical guidelines for the treatment of head and neck cancer (2020).
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number23
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC8057973.pdf
Size:
687.08 KB
Format:
Adobe Portable Document Format